|
WO2021067772A1
|
|
Axl inhibitor formulations
|
|
WO2021007316A1
|
|
Treatment of cancer
|
|
WO2021007314A2
|
|
Treatment of cancer
|
|
WO2021003417A1
|
|
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
|
WO2020191326A1
|
|
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
|
WO2020198067A1
|
|
Pkm2 modulators and methods for their use
|
|
AU2019310590A1
|
|
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
CA3095580A1
|
|
Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
|
|
KR20210003780A
|
|
AXL kinase inhibitors and uses thereof
|
|
AU2014236820A1
|
|
JAK2 and ALK2 inhibitors and methods for their use
|
